glp 1 data GLP-1 Receptor Agonist Market Growth Analysis GLP-1 anti-obesity drugs lead to

Do you need a prescription for Wegovy, Zepbound, or Saxenda

The platform facilitates the connection between patient and provider but does not practice medicine and does not guarantee any individual will receive a prescription

Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation

The FLOW trial demonstrated a 27% decrease in heart failure events among T2DM patients with CKD thus confirming their effectiveness in HF management [58]

Nature 566 , 115119 (2019)